Hopp til hovedinnhold

CIS (clinically isolated syndrome)

Sist oppdatert: Sist revidert:

  1. Thompson AJ1, Banwell BL2, Barkhof F3, Carroll WM4, Coetzee T5, Comi G6, Correale J7, Fazekas F8, Filippi M9, Freedman MS10, Fujihara K11, Galetta SL12, Hartung HP13, Kappos L14, Lublin FD15, Marrie RA16, Miller AE15, Miller DH17, Montalban X18, Mowry EM19, Sorensen PS20, Tintoré M21, Traboulsee AL22, Trojano M23, Uitdehaag BMJ24, Vukusic S25, Waubant E26, Weinshenker BG27, Reingold SC28, Cohen JA29.. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017. pmid:29275977 PubMed  
  2. Fisniku L K,. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817. pmid:18234696 PubMed  
  3. Chung KK, Altmann D, Barkhof F, Miszkiel K, Brex PA, O'Riordan J, Ebner M, Prados F, Cardoso MJ, Vercauteren T, Ourselin S, Thompson A, Ciccarelli O, Chard DT. A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Ann Neurol. 2020 Jan;87(1):63-74. doi: 10.1002/ana.25637. Epub 2019 Nov 22. PMID: 31693200; PMCID: PMC6973080.
  4. Allen CM, Mowry E, Tintore M, Evangelou N. Prognostication and contemporary management of clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2020 Dec 24:jnnp-2020-323087. doi: 10.1136/jnnp-2020-323087. Epub ahead of print. PMID: 33361410. PubMed  
  5. Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira À, Evangelou N, Wuerfel J; MAGNIMS Study Group. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol. 2019 Dec 1;76(12):1446-1456. doi: 10.1001/jamaneurol.2019.2478. Erratum in: JAMA Neurol. 2020 Aug 1;77(8):1040. PMID: 31424490 PubMed  
  6. Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016 Sep 6;87(10):978-87 . pmid: 27511182 PubMed  
  7. Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2. PMID: 28440858; PMCID: PMC6478290. The Cochrane Library  
  • Hanne Marie Bøe Lunde, spesialist i nevrologi, PhD
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med
  • Kjell Morten Myhr, spesialist i nevrologi, professor dr med